Covid vaccine: Cambridge university aims for autumn trials after United Kingdom funding

Coronavirus vaccine update coronavirus vaccine trials coronavirus vaccine China Coronavirus vaccine tracker coronavirus vaccine name Coronavirus vaccine WHO COVID19 vaccine update covid19 vaccine update India covid19 vaccine news covid19 vaccine

"Ultimately we aim to make a vaccine that will not only protect from SARS-CoV-2, but also other related coronaviruses that may spill over from animals to humans".

Even though the vaccine development process is moving at record speed, it will at least be months until a safe and effective vaccine hits the market. It has 2,000 people in the AstraZeneca Plc and University of Oxford vaccine trial, while Novavax Inc. announced earlier this month it's starting a Phase 2b clinical trial.

Normally, testing a vaccine can take five to seven years, but the anticipated Canadian clinical trials were expected to be fast-tracked through typical regulatory hurdles due to the urgency of the pandemic.

Brussels has previously said it is also in advanced talks with Johnson & Johnson, Sanofi, Moderna and CureVac for their potential vaccines. In June, the Chinese government approved the use of a different vaccine candidate for the country's military, reported CNN.

"This could be a major breakthrough in being able to give a future vaccine to huge numbers of people across the world", said Saul Faust, Director of the NIHR Southampton Clinical Research Facility.

China now has more coronavirus vaccine candidates in human trials than any other nation.

'They [India] are yet to place any proposal, ' Zahid said, adding that the government was expecting to get vaccines from China or India in December.

Companies and health officials also are working on ways to distribute COVID-19 vaccines, some of which must be shipped and stored at extremely cold temperatures.

The first vaccine, developed by the Gamaleya Research Institute of Epidemiology and Microbiology and dubbed Sputnik V, was registered in Russian Federation earlier this month.

Despite now being in Phase III testing, these results are from Phase I, and include new analysis from 20 additional people and details on how the vaccine performs in older people.

So far, officials say more than 13,000 participants have joined the late-stage study with enrollment anticipated to be completed by September and expect preliminary results as early as October.